Heparin-coated devices and high-dose aprotinin optimally inhibit contact system activation in an in vitro cardiopulmonary bypass model.
Wendel
H P
HP
Department of Thoracic and Cardiovascular Surgery, University of Tuebingen, Germany.
Heller
W
W
Gallimore
M J
MJ
D007611:Aprotinin / Q000494:pharmacology*; D001777:Blood Coagulation / Q000187:drug effects*; D002315:Cardiopulmonary Bypass / Q000379:methods*; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D004864:Equipment and Supplies / Q000009:adverse effects* / Q000592:standards*; D006493:Heparin / Q000494:pharmacology* / Q000627:therapeutic use*; D006801:Humans; D008954:Models, Biological; D010107:Oxygenators, Membrane / Q000009:adverse effects / Q000592:standards
D006493:Heparin; D007611:Aprotinin